Online inquiry

IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1794MR)

This product GTTS-WQ1794MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1794MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1297MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ12354MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ8127MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HH1
GTTS-WQ441MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 3C23K
GTTS-WQ14239MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ3306MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ7941MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ13225MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-05082566
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW